{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T08:13:26Z","timestamp":1695975206649},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T00:00:00Z","timestamp":1464134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the National Cancer Center Research and Development","award":["26-A-4"],"award-info":[{"award-number":["26-A-4"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00277-016-2690-2","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T00:35:08Z","timestamp":1464136508000},"page":"1259-1269","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy"],"prefix":"10.1007","volume":"95","author":[{"given":"Satsuki","family":"Murakami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Taji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,25]]},"reference":[{"issue":"9","key":"2690_CR1","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1046\/j.1440-1827.2000.01108.x","volume":"50","author":"Lymphoma study group of Japanese pathologists (2000)","year":"2000","unstructured":"Lymphoma study group of Japanese pathologists (2000) (2000) The world health organization classification of malignant lymphomas in Japan incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 50(9):696\u2013702","journal-title":"Pathol Int"},{"issue":"2","key":"2690_CR2","first-page":"213","volume":"19","author":"AK Ganti","year":"2005","unstructured":"Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO (2005) Follicular lymphoma: expanding therapeutic options. Oncology 19(2):213\u2013228","journal-title":"Oncology"},{"issue":"22","key":"2690_CR3","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","volume":"23","author":"WT Swenson","year":"2005","unstructured":"Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK (2005) Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23(22):5019\u20135026","journal-title":"J Clin Oncol"},{"issue":"26","key":"2690_CR4","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol 31(26):3272\u20133278","journal-title":"J Clin Oncol"},{"issue":"23","key":"2690_CR5","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol 33(23):2516\u20132522","journal-title":"J Clin Oncol"},{"issue":"5","key":"2690_CR6","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"C Buske","year":"2006","unstructured":"Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108(5):1504\u20131508","journal-title":"Blood"},{"issue":"12","key":"2690_CR7","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell\u2019olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M (2013) R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31(12):1506\u20131513","journal-title":"J Clin Oncol"},{"key":"2690_CR8","doi-asserted-by":"crossref","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4):1417\u20131423","DOI":"10.1182\/blood-2004-08-3175"},{"issue":"9759","key":"2690_CR9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Ferme C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42\u201351","journal-title":"Lancet"},{"issue":"5","key":"2690_CR10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on L","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on L (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"4","key":"2690_CR11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244\u20131253","journal-title":"J Clin Oncol"},{"issue":"5","key":"2690_CR12","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, Leblanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258\u20131265","journal-title":"Blood"},{"issue":"27","key":"2690_CR13","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Celigny P (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555\u20134562","journal-title":"J Clin Oncol"},{"issue":"4","key":"2690_CR14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.0006-341X.2000.0971.x","volume":"56","author":"TR Fleming","year":"2000","unstructured":"Fleming TR, Lin DY (2000) Survival analysis in clinical trials: past developments and future directions. Biometrics 56(4):971\u2013983","journal-title":"Biometrics"},{"issue":"1","key":"2690_CR15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/sim.4780030106","volume":"3","author":"R Simon","year":"1984","unstructured":"Simon R, Makuch RW (1984) A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 3(1):35\u201344","journal-title":"Stat Med"},{"issue":"24","key":"2690_CR16","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","volume":"26","author":"JR Anderson","year":"2008","unstructured":"Anderson JR, Cain KC, Gelber RD (2008) Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 26(24):3913\u20133915","journal-title":"J Clin Oncol"},{"issue":"9","key":"2690_CR17","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3324\/haematol.2013.100784","volume":"99","author":"J Delgado","year":"2014","unstructured":"Delgado J, Pereira A, Villamor N, Lopez-Guillermo A, Rozman C (2014) Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica 99(9):1410\u20131420","journal-title":"Haematologica"},{"issue":"8","key":"2690_CR18","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/annonc\/mdq008","volume":"21","author":"H Kato","year":"2010","unstructured":"Kato H, Yamamoto K, Matsuo K, Oki Y, Taji H, Kuwatsuka Y, Seto M, Kagami Y, Morishima Y (2010) Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. Ann Oncol 21(8):1699\u20131705","journal-title":"Ann Oncol"},{"key":"2690_CR19","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent L (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381 (9873):1203\u20131210","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"2690_CR20","doi-asserted-by":"crossref","unstructured":"Press OW, Unger JM, Rimsza LM, Friedberg JW, Leblanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI (2013) Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 31(3):314\u2013320","DOI":"10.1200\/JCO.2012.42.4101"},{"issue":"8","key":"2690_CR21","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","volume":"112","author":"D O\u2019Shea","year":"2008","unstructured":"O\u2019Shea D, O\u2019Riain C, Taylor C, Waters R, Carlotti E, MacDougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, Smeland EB, Johnson N, Campo E, Greiner TC, Chan WC, Gascoyne RD, Wright G, Staudt LM, Lister TA, Fitzgibbon J (2008) The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 112(8):3126\u20133129","journal-title":"Blood"},{"issue":"21","key":"2690_CR22","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, Leblanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351(21):2159\u20132169","journal-title":"N Engl J Med"},{"issue":"2","key":"2690_CR23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, Matthews J, Wrench D, Marzec J, Tawana K, Popov N, O\u2019Riain C, O\u2019Shea D, Carlotti E, Davies A, Lawrie CH, Matolcsy A, Calaminici M, Norton A, Byers RJ, Mein C, Stupka E, Lister TA, Lenz G, Montoto S, Gribben JG, Fan Y, Grosschedl R, Chelala C, Fitzgibbon J (2014) Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 46(2):176\u2013181","journal-title":"Nat Genet"},{"issue":"9","key":"2690_CR24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Moller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. The Lancet Oncology 16(9):1111\u20131122","journal-title":"The Lancet Oncology"},{"issue":"1","key":"2690_CR25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00277-014-2173-2","volume":"94","author":"YJ Li","year":"2015","unstructured":"Li YJ, Li ZM, Xia ZJ, Li S, Xia Y, Huang HQ, Huang JJ, Yi PY, Jiang WQ (2015) High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma. Ann Hematol 94(1):79\u201388","journal-title":"Ann Hematol"},{"issue":"10","key":"2690_CR26","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00277-014-2103-3","volume":"93","author":"M Witzens-Harig","year":"2014","unstructured":"Witzens-Harig M, Foa R, Di Rocco A, van Hazel G, Chamone DF, Rowe JM, Arcaini L, Poddubnaya I, Ho AD, Ivanova V, Vranovsky A, Thurley D, Oertel S (2014) Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol 93(10):1717\u20131724","journal-title":"Ann Hematol"},{"key":"2690_CR27","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M, Panel Members of the 1st ECCoML (2013) ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 24(3):561\u2013576","DOI":"10.1093\/annonc\/mds517"},{"issue":"7","key":"2690_CR28","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","volume":"98","author":"S Montoto","year":"2013","unstructured":"Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, Lopez-Guillermo A, Mackinnon S, Marcus RE, Salles G, Schouten HC, Sureda A, Dreger P (2013) Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica 98(7):1014\u20131021","journal-title":"Haematologica"},{"issue":"11","key":"2690_CR29","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","volume":"26","author":"A Conconi","year":"2015","unstructured":"Conconi A, Franceschetti S, Aprile Von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, Moccia AA, Bertoni F, Ramponi A, Mazzucchelli L, Cavalli F, Gaidano G, Zucca E (2015) Histologic transformation in marginal zone lymphomas. Ann Oncol 26(11):2329\u20132335","journal-title":"Ann Oncol"},{"issue":"1","key":"2690_CR30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","volume":"125","author":"C Casulo","year":"2015","unstructured":"Casulo C, Burack WR, Friedberg JW (2015) Transformed follicular non-Hodgkin lymphoma. Blood 125(1):40\u201347","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2690-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2690-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2690-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T05:50:06Z","timestamp":1559022606000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2690-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,25]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["2690"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2690-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,25]]}}}